Novo Holdings, a life science investor, led a $125m Series C funding round in Hummingbird Bioscience, a biotechnology company. The round was joined by Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group, Altium Capital, SK, Heritas Capital and Mirae. "With our world-class team of researchers and proprietary technologies, Hummingbird is at the cutting-edge of scientific discovery. These new funds give us further resources to invest in our early stage pipeline, as well as supporting the clinical development of our two lead programs that we believe can deliver very meaningful benefit for patients," Piers Ingram, Hummingbird Bioscience CEO and Co-Founder.